Țară: Taiwan
Limbă: chineză
Sursă: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)
ZOLEDRONIC ACID MONOHYDRATE
德麟有限公司 臺北市大安區敦化南路1段205號8樓之2(9021室) (52881791)
M05BA08
注射液
ZOLEDRONIC ACID MONOHYDRATE (6400001630) MG
塑膠瓶裝
製 劑
須由醫師處方使用
SciGen Pte. Ltd. 150 Beach Road, #32-05/08 Gateway West, Singapore 189720 SG
zoledronic acid
1.與標準癌症治療併用,適用於多發性骨髓瘤及固體腫瘤併有骨骼轉移之病人。用於攝護腺癌病人之骨骼轉移時,應至少接受過一種荷爾蒙治療而仍持續惡化者。2.治療惡性腫瘤之高血鈣併發症(HCM)。
有效日期: 2027/06/25; 英文品名: Zometa 4 mg / 100 ml solution for infusion
2012-06-25
www.perigord-as.com Artwork creator: Printing colours: Print enhancements: Technical colours: Cutting Artwork Order No. AW identifier No. New: Artwork Order description: Packaging site: Dimension: Tech. Drawing No.: Live text: Condensed font: Font type: Minimum font size body text: Variable data prefixes font size: Braille: AW identifier No. Old: Creation date: Proof No.: Perigord 02 Feb 2023 5 300030231 PREA ZOMETA LIVI TW 2244328-CHST N/A PS, CH, STEIN (STERILES), NTO STKaitiTC; Arial MT 9 pt N/A N/A Yes Yes No No Both 80349193_4 880.0 X 297.0 MM Dimensions TextFree Black N/A www.perigord-as.com ! P L E A S E T U R N O V E R P R I N T I N G O N ! 1 of 2 ፣౺鰚ۡৱྒ༼ध༼܈ ZOMETA ® 4 MG / 100 ML SOLUTION FOR INFUSION BISPHOSPHONATE ଋ᪥େൌއә 025734 ڦ ᱙㬒ᄺ㙻ߌ㘪̺ڕ⫲ϧ喑ᑂ䊤㙻㜌ᕔ ᾌᰰज㘪䶜㦄ߍȡ㜠㖹䚥䙽⌲䮑⢴ (CLCR) ϸ 30-49ML/MIN ⫲ϧ喑ₑ̭ᕔ ᾌᰰज倅䖁㜠 30% ȡ ᩲ CLCR<30ML/MIN ⫲ϧ喑̺ᐧ䂝Ҭ⩕᱙㬒喑 ᰶҬ⩕᱙㬒⫲ϧ喑⮳ᛶჳⰐᣔ㙻㜌ߌ 㘪ȡ̭ᬓ⮩⩌㙻㜌ߌ㘪ᘎࡃ⤫䆎喑䰭⿸ݨ ։㬒喑ᒲ㙻ߌ㘪 ( В SERUM CREATININE 㔹㼭 ) ᖏ ᓖݝധ⏃թ 10% ڔ᭯喑ज㔰᚛ᖏᓖҬ ⩕᱙㬒ȡ ੈњ땿ᖮप Ϥб 100ml ϡۡৱྒొ 4mg zoledronic acid( ѾӞؘ ) 땹ՐԵӣ 4.264mg ϡ zoledronic acid monohydrate 땾 ៅᖮ֍Ծ “ ៅᖮ ” 땾 ࡍ؝ม Ƕ ࣕࢅዓมஇѢ땹ࡍѢӣЊёՒ౺ᱏᯩ ཽրᅰᯩϭ౺ؒҮࣗϯ땾Ѣӣచঃ ዓࣗϯҮ౺ؒП땹؝ݐ׃آ֭ЪϤҡ ቫ੪ᅠஇүڝݍ੍ۉۗ땾 Ƕ இ੍ՒᅰᯩҮҶᘟёม (HCM) 땾 ѢעѢץ ፣౺鰚 (Zometa ® ) ϥЩюᘟۧղٵొՃہ۱п ( ာҰ땹ᇲ࢛યݥᠨྒ ) ϡߓᓴൌۡᨅྒඬ؏땹 ॉ؝ղٵϡେؘоѕ땹ݢѢࠂ࢘ϡߓᓴঐ ݽҝВٕϤߓᓴۡৱᨅྒ҆େ땾 өେझݔন٪ڪѢ땾 ൺя MULTIPLE MYELOMA, BREAST CANCER, PROSTATE CANCER ёЭӣ౺ۧߖЭ౺ؒҮ ࣗ༨ঀղ౺֭٢ѽֱ њѠϯюҾѠϯ Ϭൺя multiple myeloma, breast cancer, pro Citiți documentul complet